Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only is a research paper published in New England Journal of Medicine (2022). On theSindex it has a DataRank of 8.3. It has been cited 365 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.885
From this paper's citation signal
Citation Network Contribution
7.4
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NCI NIH HHS
Grant: K22 CA234400
NCI NIH HHS
Grant: P30 CA008748
AFA Försäkring
the Swedish Research Council
The Swedish Cancer Society
Karin and Christer Johansson Reaserch Foundation
Regional Cancer Center Western Region Sweden
Nordic Cancer Union
National Institutes of Health/National Cancer Institute to Memorial Sloan Kettering Cancer Center
MeSH Terms
Additional file 1 of Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators
Additional file 1 of Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators
Additional file 4 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 4 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 5 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 5 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 1 of Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
Additional file 1 of Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?
Additional file 2 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 2 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 3 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 1 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 3 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
Additional file 1 of ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003